Connect Biopharma Holdings Limited
CNTB
$2.12
-$0.08-3.64%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | -98.69% | -99.80% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -100.00% | -98.69% | -99.80% | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -100.00% | -98.69% | -99.80% | -- |
| SG&A Expenses | -1.41% | 3.99% | 32.83% | 6.26% | 21.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 72.76% | 50.49% | 33.38% | 48.53% | -9.39% |
| Operating Income | -71.29% | -61.41% | -46.75% | -189.22% | 9.39% |
| Income Before Tax | -89.37% | -71.39% | -33.70% | -186.33% | -17.95% |
| Income Tax Expenses | -11.11% | -74.53% | 7.02% | 83.33% | 80.00% |
| Earnings from Continuing Operations | -88.84% | -69.65% | -33.58% | -186.88% | -18.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -88.84% | -69.65% | -33.58% | -186.88% | -18.16% |
| EBIT | -71.29% | -61.41% | -46.75% | -189.22% | 9.39% |
| EBITDA | -72.46% | -62.19% | -47.41% | -187.14% | 9.58% |
| EPS Basic | -84.86% | -67.39% | -32.49% | -186.39% | -17.62% |
| Normalized Basic EPS | -85.36% | -69.11% | -54.33% | -178.46% | -17.40% |
| EPS Diluted | -84.86% | -67.39% | -32.49% | -186.39% | -17.62% |
| Normalized Diluted EPS | -85.36% | -69.11% | -54.33% | -179.19% | -17.40% |
| Average Basic Shares Outstanding | 2.16% | 1.37% | 0.84% | 0.57% | 0.45% |
| Average Diluted Shares Outstanding | 2.16% | 1.37% | 0.84% | -0.38% | 0.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |